Invivyd, Inc. — Director's Dealing 2022

Aug 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2022-08-17

Reporting Person: Elia Marc (Director, See Footnote 5)
Reporting Person: M28 Capital Management LP (See Footnote 5)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-17	Common Stock	P	1000000	$4.04	Acquired	7398250	Indirect
2022-08-18	Common Stock	P	1265549	$4.31	Acquired	8663799	Indirect
2022-08-19	Common Stock	P	584451	$4.62	Acquired	9248250	Indirect

Footnotes

F1: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $3.96 to $4.15.

F2: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $3.90 to $4.50.

F3: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $4.33 to $4.70.

F4: The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

F5: This Form 4 is filed by M28 Capital Management LP ("M28 Capital Management") and Marc Elia ("Mr. Elia") with respect to securities held by certain funds and accounts for which M28 Capital Management serves as investment manager. Mr. Elia is the Chief Investment Officer of M28 Capital Management and the Managing Member of M28 Capital Management GP LLC, the general partner of M28 Capital Management. Mr. Elia also serves on the Board of Directors of the Issuer. The Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.